Adenosine triphosphate injection

Drug Profile

Adenosine triphosphate injection

Alternative Names: ATPace

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator Duska Therapeutics
  • Developer Cordex Pharma
  • Class Adenine nucleotides; Antiarrhythmics; Infertility therapies; Small molecules
  • Mechanism of Action Purinergic P2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bradycardia; Paroxysmal supraventricular tachycardia

Most Recent Events

  • 02 Jun 2009 The US FDA approves Special Protocol Assessment (SPA) design of phase IIb/III trials for Paroxysmal supraventricular tachycardia
  • 20 Feb 2009 Cordex Pharma submits to the US FDA an amended phase III trial protocol for Paroxysmal supraventricular tachycardia
  • 20 Nov 2008 Duska Therapeutics applies for a Special Protocol Assessment with the US FDA to conduct a pivotal phase III trial for Paroxysmal supraventricular tachycardia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top